

CITATION REPORT

List of articles citing

Radiological progression in rheumatoid arthritis: do D-penicillamine and hydroxychloroquine have different effects?

DOI: 10.1093/rheumatology/29.2.126
Rheumatology, 1990, 29, 126-7.

Source: <https://exaly.com/paper-pdf/21706408/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|---|--|-----|-----------|
| 9 | Chondroprotection. <i>Lancet, The</i> , 1991 , 337, 769-770 | 4.0 | 1 |
| 8 | The impact of endpoint measures in rheumatoid arthritis clinical trials. <i>Seminars in Arthritis and Rheumatism</i> , 1992 , 21, 287-94 | 5.3 | 24 |
| 7 | The course and outcome of rheumatoid arthritis. Radiological measures of outcome. <i>Baillière's Clinical Rheumatology</i> , 1992 , 6, 39-67 | | 2 |
| 6 | Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. <i>Arthritis and Rheumatism</i> , 1992 , 35, 1117-25 | | 186 |
| 5 | Clinical pharmacokinetics of slow-acting antirheumatic drugs. <i>Clinical Pharmacokinetics</i> , 1993 , 25, 392-407. | 6.2 | 67 |
| 4 | Penicillamine for treating rheumatoid arthritis. <i>The Cochrane Library</i> , 2000 , | 5.2 | 10 |
| 3 | Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. <i>Health Technology Assessment</i> , 2014 , 18, i-xxiv, 1-164 | 4.4 | 17 |
| 2 | Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 348 | 2.8 | |
| 1 | Risk factors and risk-benefit problems in the use of DMARDs. <i>Inflammation and Drug Therapy Series</i> , 1992 , 311-320 | | 1 |